In the Pipeline and Under Study
Our goal is to cure cancer. That’s why, in addition to seeing patients, all physicians on our Myelodysplastic Syndromes (MDS) team conduct research aimed at finding ways to improve treatment. By offering new therapies or new combinations of drugs through clinical trials, we can provide options that are potentially more effective than standard treatments. Ongoing research also helps us better understand how the disease works so we can develop new, targeted therapies for unique MDS subtypes.
We are active participants in the Alliance for Clinical Trials in Oncology, a group of cancer centers that conduct clinical research trials together and share information in an effort to speed cancer cures.
We’re also collaborating with Lucy Godley, MD, PhD, the Hospira Foundation Professor of Medicine and Human Genetics at UChicago Medicine, to better understand inherited blood cancer risk.
Translational research, which aims to bring new discoveries to the clinic to help patients as quickly as possible, is a major focus of the work of Roswell Park’s MDS and Leukemia teams. Our strong research program — with about 20 clinical trials open at any given time for MDS and leukemia patients — provides our patients with more treatment options to maximize their survival. All of our MDS and leukemia patients undergo appropriate diagnostic tests to determine whether a targeted therapy is available for their disease subtype, sometimes as part of a clinical trial.
Roswell Park maintains one of the first clinical research centers in the nation that focuses specifically on the development of new cancer treatments. Our Clinical Research Center (CRC) has enabled us to expand our program of phase I clinical trials, which represent the first step toward FDA approval of a new treatment. The CRC upholds the highest level of patient safety and quickly generates precise data on potential new treatments. As a result, Roswell Park’s MDS team can offer patients access to treatments that might not be available to them through other cancer care providers.
Currently we are examining:
- Vaccine strategies that could improve how well chemotherapy works against MDS
- The development of new drugs for MDS, which could be given alone or in combination with other drugs
- Studies of genetic pathways and proteins involved in MDS, which could lead to new targeted therapies
- How MDS develops, and its potential interactive role with mitochondrial biology with the cell
- The specific ways in which azanucleotide therapy works
- How MDS is affected by the genetic underexpression or overexpression of genes involved in the immune system
Search online for available clinical research studies for MDS patients at Roswell Park, or call 1-800-ROSWELL (1-800-767-9355).